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Abstract: Cyanobacteria are an inspiring source of bioactive secondary metabolites. These bioactive agents are a diverse group 
of compounds which are varying in their bioactive targets, the mechanisms of action, and chemical structures. Cyanobacteria 
from various environments, especially marine benthic cyanobacteria, are found to be rich sources for the search for novel 
bioactive compounds. Several compounds with anticancer activities have been discovered from cyanobacteria and some of these 
have succeeded to enter the clinical trials. Varying anticancer agents are needed to overcome increasing challenges in cancer 
treatments. Different search methods are used to reveal anticancer compounds from natural products but cell based methods are 
the most common. Cyanobacterial bioactive compounds as agents against acute myeloid leukemia are not well studied. Here we 
examined our new results combined with previous studies of anti-leukemic compounds from cyanobacteria with emphasis to 
reveal common features in strains producing such activity. We report that cyanobacteria harbor specific anti-leukemic compounds 
since several studied strains induced apoptosis against AML cells but were inactive against non-malignant cells like hepatocytes. 
We noted that particularly benthic strains from the Baltic Sea, such as Anabaena sp., were especially potential AML apoptosis 
inducers. Taken together, this review and re-analysis of data demonstrates the power of maintaining large culture collections for 
the search for novel bioactivities, and also how anti-AML activity in cyanobacteria can be revealed by relatively simple and low-
cost assays. 
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1. INTRODUCTION 
 Most, if not all leukemia patients, and particularly those 
with acute myeloid leukemia (AML) rely on heavy 
chemotherapy to control the disease in the initial phase of the 
therapy (induction remission therapy). Despite intensive 
research to develop novel chemotherapy, most AML patients 
receive treatment regimens developed several decades ago 
[1]. The majority of drugs in use today, including the preferred 
anti-AML drug daunorubicin (DNR) originate from natural 
compounds, and microbes from the entire biosphere continue 
to be the major source of these valuable compounds [2-4]. 
Marine organisms are especially interesting; while oceans 
cover most of the earth`s surface, the terrestrial environment 
has so far been the most explored with respect to bioactive 
compounds.     
 Cyanobacteria are photosynthetic prokaryotes that are 
highly abundant and diverse in all aquatic and terrestrial 
environments [5, 6]. The versatility of cyanobacteria is also 
seen in a wide variety of secondary metabolites that they 
produce [7], reflected by the diversity of bioactivities 
associated with these sometimes structurally complex 
molecules. Whereas some compounds are toxic and pose a 
direct health risk to humans and domestic animals, others have 
antifungal, antibiotic, antiviral activities, or selectively inhibit 
enzymes and functions in mammalian cells [4, 7-9]. 
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   Cyanobacteria are, along with heterotrophic bacteria, the 
most potent organisms in marine environments producing 
bioactivities that can lead to pharmaceutical agents [10]. 
Cyanobacterial bioactive compounds include peptides, 
polyketides, peptide-polyketide hybrids, alkaloids and 
polysaccharide structures produced through ribosomal, non-
ribosomal, or hybrid pathways (Fig. 1) [11-13]. Moreover, 
each compound usually exists in several different variants, 
exemplified with the aeruginosin family, which nowadays 
includes over 50 variants differing in chemical structure and 
enzyme inhibition abilities [14, 15]. An intriguing feature of 
some cyanobacterial compounds is their ability to selectively 
induce cell death in human cancer cells. Anticancer 
compounds have been studied through different methods 
perhaps most commonly via cell based assays and a large 
number of different compounds with anticancer activity have 
been discovered until today. In the following section, we will 
give some examples of potent anticancer compounds isolated 
from cyanobacteria. 
1.1. Anticancer compounds from cyanobacteria 
Anticancer compounds from cyanobacteria affect the cells 
by different mechanisms of action, such as interruption of 
cytoskeletal structures, modulation of signaling pathways or 
enzymes, or interaction with DNA [16, 17]. Dolastatins (Fig. 
1), for instance affect cell division by disrupting the 
microtubule function [18]. Dolastatins were first isolated from 
sea hare Dolabella auricularia but were later found to be 
produced by the cyanobacteria Symploca sp. and Lyngbya 
majuscula, on which the sea hare feeds [19-21]. In the 
following years the highly potential antineoplastic compounds 
dolastatin 10 and 15 were discovered [22, 23] and they went 
through the first phases of clinical trials, but were 
discontinued due to severe side effects. Still, studies on 
dolastatin have continued and several improved synthetic 
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analogs have been demonstrated. Brentuximab vedotin 
(Adcetris®) is composed of monomethyl auristatin E, a 
synthetic analogue of dolastatin 10, and monoclonal antibody 
CD30.  It has been approved by FDA to the treatment of 
Hodgkin`s lymphoma and anaplastic large cell lymphoma 
[24]. Other promising auristatin E and antibody conjugates are 
also being evaluated in different phases of clinical trials [25]. 
 
 
Fig. 1. A selection of cyanobacterial anticancer compounds. 
Another group of microtubule disruptors is the 
cryptophycins (Fig. 1). Cryptophycin A was isolated from 
Nostoc sp. GSV224 and it was found to exhibit anticancer 
activity toward several cancer cell types including multi-drug 
resistant tumor cell lines [26, 27]. The activities of 
cryptophycins were improved by constructing chemical 
analogs and cryptophycin-52 entered a clinical trial, but 
lacked efficacy in phase II studies [28]. More analogs are 
presented, together with targeting molecules, such as antibody 
conjugates [29, 30]. Curacin A (Fig. 1) is another compound 
affecting cell cycle via microtubulins [31]. It was found early 
in the 90's and was described toxic to brine shrimps and to be 
an antimitotic compound [32]. Despite some unfavorable 
properties, chemical modifications improving solubility and 
stability were made without affecting biological activity [33, 
34]. The newly discovered bisebromoamide (Fig. 1) from 
Lyngbya sp. was shown to affect cell structure through 
interaction with actin filaments in a morphology profile study 
[35, 36]. The first studies showed activity at nanomolar 
concentrations against a panel of human cancer cell lines and 
recently it was demonstrated to have apoptotic effect against 
certain renal cancer cell lines by inhibiting P13K/Akt/mTOR 
and Raf/MEK/ERK signaling pathways [35, 37]. 
Different Lyngbya species have been a rich source of 
anticancer compounds. Apratoxins (A-E) (Fig. 1) is another 
group of compounds collected originally from Lyngbya sp. 
harboring cytotoxic properties [38-40]. Apratoxin A was first 
described to cause cytotoxicity to human solid tumor cell 
lines. Later the range of the target cancer cell lines has been 
extended. Apratoxins were shown to inhibit several cancer-
associated receptors in the secretory pathway but also target 
the heat shock proteins (Hsp 90) [41-43]. As with curacin A, 
the antitumor activity and selectivity of apratoxins were 
improved by hemisynthesis of analogs [44, 45]. Potential 
lipopetide somocystinamide A (Fig. 1) from L. majuscula can 
activate a caspase-8-dependent cell death pathway in tumor 
cell lines for instance in Jurkat cells [46, 47] and 
cyclodepsipeptide aurilide targets prohibitin 1 initiating 
apoptosis by mitochondrial-mediated pathways [48]. 
Aurilides and their naturally occurring variants such as 
lagunamides (Fig. 1) exhibit cytotoxic features against cancer 
cell lines [49-52]. In addition, lagunamides show potential 
antimalarial activity against Plasmodium falciparum [51, 53].  
Largazole (Fig. 1) is an interesting cyanobacterial 
anticancer compound that inhibits class I histone deacetylases 
[54, 55]. Inhibition of the histone deacetylases (HDAC) has 
become an attractive drug target particularly in cancer 
chemotherapy, and several HDAC inhibitors are used against 
AML [56]. Largazole was isolated from Symploca sp. from 
Key Largo, Florida and it showed strong selective activity 
against cancer cell lines [57, 58]. This compound is defined as 
prodrug, which is converted into active thiol compound. 
Several total syntheses and structural modifications of 
largazole have been performed, extending the target diseases 
from colorectal carcinoma and other cancers to osteoporosis, 
liver fibrosis, corneal neovascularization etc. [59-61]. Novel 
carmaphysins (A, B) (Fig. 1) exhibited nanomolar 
cytotoxicity to human lung adenocarcinoma and colon cancer 
cell lines in addition to inhibition to 20S proteasome of 
Saccharomyces cerevisiae [62]. Further studies have been 
initiated on the total synthesis and to investigate proteasome 
inhibition complex [62, 63]. Symplocamide A (Fig. 1) has 
been identified as chymotrypsin inhibitor with cytotoxic 
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features [64]. It shows nanomolar activity against lung cancer 
and mouse neuroblastoma cell lines. Symploca sp. from Papua 
New Guinea is producing symplocamide A and its total 
synthesis was described being the first solid phase synthesis 
of an aminohydroxypiperidone (Ahp) cyclodepsipeptide [64, 
65]. 
There are in addition numerous anticancer compounds 
detected in cell-based assays where the exact mechanism of 
action is not yet identified. Dragonamide C and D from 
Lyngbya polychroa were reported to have weak antimitotic 
activity against osteosarcoma, colon adenocarcinoma and 
neuroblastoma cells [66]. Minutissamides A-D from 
Anabaena minutissima were described to have varying 
antiproliferative activity against human colon cancer cell line 
[67]. Recently a group of novel almiramides (D-H) was 
identified from Oscillatoria nigroviridis along with the 
known compound almiramide B [68]. The organic extracts 
showed promising activities but in further studies the 
compounds indicated only mild activity against human cancer 
cell lines and stronger activity against gingival fibroblast cell 
line used as an example of a primary cell line. The first 
almiramide molecules (A-C) were tested primarily against 
Leishmanias studying possible antiparasite effects but also 
these compounds showed cytotoxic effects on Vero cell line 
from monkey kidney [69]. Although the first cell based 
studies did not show significant selectivity, the modification 
of the structures may be a significant step in designing 
compounds with specific targets. Similarly the studies of the 
mechanism of action play a key role in improving the 
bioactivity. Lead compounds can be tested for properties with 
anticancer drugs to detect synergistic effects. Synergistic 
improvements have been described for instance in study 
where photosynthetic accessory pigment C-phycocyanin was 
tested with topotecan against prostate cancer cell lines and in 
other study where cyanobacterial crude extract and the anti 
AML-drug daunorubicin were tested against acute myeloid 
leukemia cell line [70, 71]. In conclusion, cyanobacteria 
remain a rich source for bioactive compounds with potential 
as anticancer drugs or leads, depicted by the high discovery 
rate of novel compounds. Developments of detection methods 
and sensitivity of instruments have brought improvements 
which have decreased the sample amount needed to detect and 
describe the active compounds and this hopefully hastens the 
study paths from potential natural extract to drug lead trough 
structure elucidation, total synthesis and unraveling the 
mechanism of action [10]. 
1.2. Methods for screening cyanobacterial strains for 
anticancer activity 
 During the last decades, screening programs for bioactive 
compounds from natural sources has driven the development 
of high-throughput methods, often in combination with 
advanced computational biology or bioinformatics [72]. 
Unfortunately, data from such large screening programs often 
remain unpublished, hindering any external evaluation of the 
methods behind the selection procedure, and more 
importantly, making it difficult to compare the screening 
results from different laboratories and culture collections. We 
will here give a brief introduction to some methods used to 
detect anticancer activity, and the type of information 
available with the different bioassays.  
1.2.1. Cell-based assays: 
 Cell based assays are one of the most used to screen for 
anticancer compounds. Such assays have the advantage that 
they can be used in automated high-throughput screens, and a 
number of cell lines, relevant for different diseases are 
commercially available. In addition, several companies offer 
standardized screens on cell panels, and the National Institute 
of Health in the USA offers screens on 60 tumor and normal 
cell lines [75, 76]. Moreover, such assays allow for testing on 
primary cell lines as well as non-immortalized cell samples 
from patients [77, 78]. A particular advantage with cell assays 
is that these are compatible with different types of samples, 
ranging from crude extracts to HPLC-fractions, or purified 
compounds. A selection of a few cell lines is often chosen to 
screen a whole culture collection [79-82] and selected extracts 
or purified compounds are scrutinized for anticancer effect on 
a large panel of cancer and normal cell lines [70, 83] often 
combined with chemical analyses of extract to find the 
compound of interest [84].    
 It is crucial to critically choose the methods used to record 
toxicity in cell based assays. Colorimetric assays like the 
tetrazolium-based assays for metabolic activity and assays to 
measure e.g. ATP-levels or conversion of pro-caspase-3 to 
caspase-3 are widely used, and are compatible with automated 
high-throughput screens. However, any assay based on 
intensity of a light signal will be affected by the sometimes 
large quantity of pigments present in a crude extract, 
increasing the risk of false positive or negative results. The 
metabolic-based assays usually rely on reduction of a 
substrate, and if a toxin increases levels of reactive oxygen 
species (ROS) in a cell, this can create a higher turnover of 
substrate. In these instances, different methods must be 
considered. Microscopic analyses of cell populations give 
more information than colorimetric assays, such as the state 
of cells (necrotic, apoptotic, mitotic etc.) but will not be able 
to detect for instance growth inhibition. Moreover this is a 
cumbersome method, relying much on manual work. 
Although automated microscopes and software can aid in 
quantification, some cell lines and samples still demand 
manual assignment of cell morphology. Also, there are cases 
where the cell death cannot be recognized morphologically, 
which will produce false negatives [85]. Flow-cytometry 
based assays (like staining for apoptosis marker AnnexinV 
and the necrosis marker propidium iodide) is perhaps more 
costly than the previous methods, but can be automated to fit 
for instance 96-well plates. However, this method is also best 
suited with clean extracts or fractions, without particulates or 
remnants of sediments.    
 A general rule is that to be certain of cell death induction, 
two biochemically unrelated methods should be used. 
However during the initial screen for bioactivity, the main 
focus should be to eliminate negative fractions, and more 
emphasis should be put into the analyses in the secondary 
screens of selected fractions/extracts. There is a balance 
between quality of the data, and the quantity of samples or 
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extracts to be analyzed. A particular problem arose when we 
screened benthic cyanobacterial extracts for antileukemic 
activity. A number of aqueous extracts were toxic to a 
selection of AML cell lines [70, 82], and a study on marine 
diatoms suggested that this could be due to adenosine-like 
activity [86]. Co-incubation of cells with cyanobacterial 
extracts and adenosine deaminase (ADA) eliminated the 
toxicity in many extracts, suggesting that the toxicity was an 
ADA-sensitive nucleotide [82]. AML-cells have been shown 
to be sensitive to adenosine through adenosine receptor 2 [86, 
87]. A way to circumvent the adenosine-related toxicity was 
to use serum without heat inactivation in the cell medium [82]. 
The ADA present in the serum will then convert adenosine- 
or toxic adenosine analogues to the inactive inosine or 
deaminated analogs. 
1.2.2. In vitro biochemical assays: 
 Assays detecting a particular biochemical process, like 
enzyme activity, are commonly used when a particular drug 
target is identified. In modern drug development, this has 
become more popular, since genomic analyses of large patient 
cohorts make it possible to extract poor prognosis factors for 
instance in cancer therapy. This approach led to the discovery 
of the microtubulin-interacting compound tubercidin (Fig. 1) 
from cyanobacteria [88]. There are numerous of targets 
identified as particularly interesting for AML, including cell 
signal modulator like tyrosine kinases such as FMS-like 
tyrosine kinase 3 (FLT3), mammalian target of rapamycin 
(mTOR), Janus-associated kinase (JAK), or inhibitors of cell 
functions like proteasome, epigenetic regulators of gene 
expression (DNA methyltransferase), histone deacetylase, 
and disruptor of telomeric signaling-1, to mention a few [89]. 
In vitro assays measuring for instance enzyme activity fits 
well with an automated high-throughput program, with the 
ability to test several thousand samples and fractions within a 
short time-frame. A drawback, however, is that when 
searching for anticancer compounds, there is a risk that 
anticancer compounds acting on different proteins will not be 
detected. Again, one has to balance the benefits of high-
throughput assays to the quality of data using more high-
content-focused assays.    
 In silico screen to find structural related compounds or 
drug targets emerge as a powerful tool to identify drug 
candidates. For this, one needs an identified target, a structure, 
a scaffold, or the pharmacophor model of an active compound. 
Moreover, a chemical compound-library is needed. This last 
point may restrict the usefulness of cyanobacterial compound 
libraries, since they do not have the same number of 
compounds compared to commercially available compound 
libraries. Moreover, the complexity of many cyanobacterial 
secondary metabolites with their numerous different 
conformers makes it difficult to get reliable docking data with 
a high-throughput virtual screen. Still, El-Elimat and 
coworkers [90] compared secondary metabolites from 
cyanobacteria with anticancer compounds with focus on nine 
sets of chemical properties, showing that cyanobacterial 
compounds partly aligned well with FDA-approved 
anticancer drugs. It appears thus more likely to identify 
interesting compounds by searching for structural moieties 
related to a known activity, and then use a genomic- or LC-
MS guided screen to identify lead compounds. The latter was 
used to identify novel cyanobacterial cyclic peptides 
containing 4-methylproline, which has the ability to inhibit 
liver-transporters [91].   
1.2.3. Biosynthesis and genome based methods: 
The biosynthetic gene clusters of many cyanobacterial 
bioactive compounds have been revealed during the last 15 
years, which have allowed for the development of new DNA 
based methods in order to predict the production of 
compounds [92-94]. These methods can be added into 
traditional bioactivity screening methods for finding new 
potential producers and identifying the producers of known 
toxic compounds. Both ribosomal and non-ribosomal 
biosynthetic pathways for cyanobacterial bioactive 
compounds have been described [95-97]. Cyanobacteria have 
shown to be a rich source of nonribosomal biosynthetic 
pathways along with the myxobacteria, pseudomonads and 
streptomycetes by using genome mining tools [97]. NRPS and 
PKS gene clusters are widely distributed in the cyanobacteria 
as well as ribosomal pathways occur commonly [97-99]. 
Genome mining reveals new insights into bioactive product 
discovery when gene clusters can be identified before 
knowing the target of activity [91, 98, 99]. This method can 
be used to find putative gene clusters and further attached to 
structural analysis to reveal the novel compounds. Genome 
based methods can unveil those compounds that are not 
detected in bioassay testing due to low amounts of bioactive 
compounds or inactive genes.    
 A high number of bioactive compounds have been found 
from cyanobacteria and those identified with anticancer 
activities represent a highly varied group of different chemical 
structures. Previously in our laboratories we have screened 
anti-leukemic compounds from cyanobacteria and found high 
frequency of interesting bioactivities [70, 77, 82]. In the 
following sections, we will re-analyze our findings from 
previous work together with additional new screening results, 
to reveal possible links between bioactivities and genus, 
sampling site and others, with emphasis on anti-leukemic 
activity. The results can be used as a guide to the search for 
novel anti-cancer compounds in future screening programs.  
 
2. MATERIALS AND METHOD 
2.1. Cyanobacteria strains and extracts 
 The cyanobacteria strains analyzed here were from 
Cyanobacterial Culture Collection of University of Helsinki 
(HAMBI) and were isolated from Baltic Sea cost areas, 
mainly in benthic habitats [77, 82] and  some symbiotic strains 
were also used, mostly isolated from lichen Peltigera sp. [82] 
(Supplementary Table 1.). In addition, we have included 
unpublished data from strains collected from various locations 
including limnic habitats (Supplementary Table 1.). 
Cyanobacteria were identified using morphological methods 
[77] and/or sequencing of 16S rDNA genes [82]. Each strain 
was cultured in Z8 or Z8X medium at 20 °C under continuous 
light in 15 µmol m-2 s-1 [77, 82]. The cells grown 20-60 days 
in 3 liter volume of medium were harvested, freeze dried and 
extracted [77, 82]. We analyzed separately the aqueous and 
organic (methanol or 1:1 methanol:dichloromethane) extracts. 
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The previously unpublished cyanobacteria strains were 
treated as in Liu et al. [82]. Cyanobacterial DNA was 
extracted using E.Z.N.A. SP Plant DNA Mini Kit (Omega 
Bio-Tek Inc.). The cells were first disrupted using twice 
FastPrep™ for 30 s at 6.5 m s-1 and then followed 
manufacturer's instructions in extraction protocol. The 16S 
rRNA genes were amplified by PCR, cloned into pCR®2.1 -
vector and clones were sequenced and aligned as described 
before [100]. 
2.2. Cell lines and cytotoxic assays 
 Cyanobacterial extracts were tested for their ability to 
induce apoptosis in primary rat hepatocytes in suspension, and 
in the human AML cell line Molm13 (acute monocytic 
leukaemia with the poor prognostic factor FLT3 internal 
tandem duplication) [101] or the rat AML cell line IPC-81 
(derived from the BNML, acute promyelocytic of neutrophil 
lineage) [102]. The primary rat hepatocytes were isolated by 
in vitro collagenase perfusion [103, 104]. Experimental 
conditions were as described in detail in [77]. Hepatocytes are 
particularly suited to detect variants of the common 
cyanotoxins microcystin and nodularin, which are specifically 
transported into the cells through the liver-specific transporter 
proteins OATP1B1 and 1B3. In some cases, we used 
HEK293T (Human embryonic kidney cells, ATCC no: CRL-
11268) transfected with OATP1B3 or 1B1 [105] to detect 
liver-selective toxins, and this has proven to be a reliable cell-
based assay to detect such activity, and is also sensitive for 
variants not detected by LC-MS [82]. For cell death assays, 
cells were dissolved in fresh medium, added extracts in 
concentrations from 0.1 to 1% or the corresponding volume 
of solvent for control, incubated overnight together with 
extracts and results were assessed by microscopy as described 
before [82]. We eliminated adenosine effect detected in 
previous studies [70, 82] by using serum that was not heat-
inactivated to supplement the culturing medium. Such serum 
contains active adenosine deaminase, which converts 
adenosine to inactive inosine. Experiments on AML and 
HEK293T cells were performed in 0.1 mL in 96 well tissue 
culture plates, and the HEK293T cells were allowed to rest for 
24 h to attach to the substratum before addition of extracts.  
2.3. LC-MS analysis of cyanobacterial extracts 
 We further analyzed the extracts that showed cytotoxic 
activities with LC-MS, to detect any known cytotoxic 
compounds. Cyanobacteria were extracted similarly as for 
cytotoxic tests and LC-MS was performed on an Agilent 1100 
Series LC-MSD TRAP System HPLC (Agilent Technologies, 
Palo Alto, CA, USA) with XCT Plus model ion trap mass 
detector. Ten microliters of samples were separated on a Luna 
C8-(2) column (150 x 2 mm, 5 μm, Phenomenex, Torrance, 
CA, USA) eluted 0.15 ml min-1 with 0.1% aqueous HCOOH 
(A) and isopropanol (+ 0.1 % HCOOH) (B) starting from 5 % 
B to 100 % B in 35 minutes at 40°C. Mass spectra were 
acquired using electrospray ionization in positive mode, Ultra 
Scan mode and scan range of m/z 200 – 1100. 
3. RESULTS AND DISCUSSIONS 
3.1. Summary of the new data included in the study 
 Several studies have shown that cyanobacteria produce a 
great number of diverse apoptosis inducing compounds 
effective against leukemia cells [70, 77, 79, 82, 106]. The new 
unpublished results are in line with our previous findings [70, 
77, 82] showing divergent and high amount of apoptotic 
activities (Fig. 2). About 48 % of these  43 cyanobacteria 
strains studied showed high (over 70 %) cell death activity 
toward either of the cells used, and 32 % showed selective 
activity towards AML cell lines (Supplementary Table 2.). 
Organic extracts from samples HIID B16A, Microcystis sp. 
Izancya 30 and 7 stood out from other results by being highly 
cytotoxic towards all cell lines tested for. These extracts 
presented nonspecific activities. For our purpose, namely anti-
AML activity, strains like Trichormus sp. HIID D3, Anabaena 
sp. HIID D7A, Leptolyngbya sp. HIID D2A and HIID B21B 
were more interesting, showing high activity against Molm13 
cells but less towards IPC-81 cells or hepatocytes. 
 Extracts of strains Nostoc sp. XHIID C2 and Calothrix sp. 
XPORK 9A showed strong activity towards Molm13 cells and 
moderate activity against IPC-81 cells, but were inactive 
towards hepatocytes. Similarly a group of Planktothrix sp. 
strains (Planktothrix sp. 18, 127, 251, 278, 289) showed high 
activity against Molm13 cells together with high or moderate 
activity against IPC-81 cells without hepatocyte activity. On 
the contrary Microcystis sp. Izancya 43 and 31 were active 
only against hepatocytes, suggesting the presence of 
microcystin or nodularin-like compounds. Only few strains 
showed activities in both aqueous and organic extracts. 
Organic extracts were altogether more active and the most of 
the strong activities were detected in organic extracts. One 
exception was the activity of the strain Nostoc sp. HIID D1B 
where the aqueous extract caused apoptosis in Molm13 wild 
type cell line as well as in hepatocytes. Overall, IPC-81 and 
Molm13 cells responded similarly to the cyanobacterial 
extracts but the Molm13 cell line seemed to be slightly more 
susceptible to cyanobacterial extracts (Fig. 3). We conclude 
that both cell lines can be used to detect anti-AML activity 
from cyanobacterial extract.   
 The studied cyanobacteria strains were identified based on 
the 16S rRNA gene sequencing and they were widely 
distributed in the phylogenetic tree (Supplementary Fig. 1.). 
The biggest studied genus group was Planktothrix sp. along 
with Microcystis sp. while other genera had one or two 
representatives. Especially some strains from Lake Hiidenvesi 
were found to have only few near neighbors. Some of these 
strains were showing only 93 % similarity in BLAST searches 
(NCBI) but they were roughly named based on the BLAST 
searches and morphology. 
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Fig. 2. The heat map with clustering analysis of all the four studies. 
LO = Leukemia cell death (IPC-81) in organic extracts (%). HO = 
Cell death activity (%) against non-malignant cells (hepatocyte or 
HEK293T cells transfected with OTAP1B1 or 1B3) in organic 
extracts. LA = Leukemia cell death (IPC-81) in aqueous extracts. HA 
= Cell death activity (%) against non-malignant cells (hepatocyte or 
HEK293T cells transfected with OTAP1B1 or 1B3) in aqueous 
extracts. The apoptotic activities are presented in darkening colors 
from white (0 %) to bright red (100 %). The heat map was clustered 
according to activities in R (version 3.1.1.) [107] by using function 
heatmap.2 in package gplots [108]. G = Growth habitats of the strains 
(blue: benthic, green: sediment, brown: planktonic, grey: symbiotic). 
S = Sampling places of the strains (blue: Baltic Sea, black: terrestrial, 
green: lake, yellow: other limnic isolation places). 
 
 
 
Fig. 3. The new unpublished data of IPC-81, Molm13 and hepatocyte 
cell death (%) caused by aqueous and organic extracts. The x-axis is 
the IPC-81 cell death (%) minus hepatocyte cell death (%) and the y-
axis is the Molm13 cell death (%) reduced from hepatocyte cell death 
(%). The green planktonic, aqueous extracts such as Planktothrix sp. 
127 (Pl. 127) and Phormidium sp. 214 (P. 214) were especially 
potential IPC-81 cell death inducers selectively as they were not 
active against hepatocytes. The organic extracts were more active 
against Molm13 cells and many organic sediment samples like 
Leptolyngbya sp. HIID D2A (L. D2A) was selectively active against 
Molm13 cells. Some organic extracts such as Planktothrix sp. 289 
and 127 (Pl. 289, Pl. 127) were active for both AML cell lines, but 
they were slightly more active against Molm13 cells. In the other 
corner of the figure there are extracts that were selectively active 
against hepatocytes (Microcystis Izancya 43, 31 and 15 [M. I43, M. 
I31, M. I5]). In addition, the strains showing equal activities against 
IPC-81, Molm13 and hepatocyte cells come to the zero point. The 
aqueous extract of Nostoc sp. HIID D1B (N. D1B) was totally 
different from others by producing apoptosis against hepatocytes and 
Molm13 cells but not IPC-81 cells.  
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3.2. Different study cases provided similar results 
 In this study, in addition to the summarized new results (in 
section 3.1.) we analyzed additional datasets from previous 
publications [70, 77, 82] in order to reveal new aspects and 
improvements in the search for anti-leukemic activity from 
cyanobacteria strains. In general, the cyanobacterial extracts 
showed high content of bioactivity. The heat map illustrates 
the apoptosis inducing activity against the AML cell line IPC-
81 together with either primary hepatocytes or HEK293T cells 
transfected with OTAP1B1 or 1B3 of the four studies (Fig. 2). 
In the dataset of Herfindal et al. [77] and Oftedal et al. [70] 14 
strains out of 43 showed high (above 70 %) anti-leukemic 
activity from which five strains exhibited a specific activity 
toward AML cells. From the study of Liu et al. [82] four 
strains out of 40 showed high activities, where two were 
selective towards AML cells. The new unpublished data 
included five strains with high AML-activity and two of them 
were specifically active against IPC-81 cell line. Although 
each study was separate and the starting point divergent from 
another the results were very similar. Together, these studies 
illustrate the potential of cyanobacteria in producing bioactive 
compounds that selectively induce apoptosis in AML cells. 
The results of these studies were not completely comparable 
due to the differences in methods. For instance, the extraction 
protocol differs, being a sequential extraction [70, 77] or a 
two-phase extraction [82]. Also, we now excluded activities 
such as adenosine-like activity from the two recent studies 
[82], which could explain the higher amount of activities in 
the first studies [70, 77].    
 The heat map illustrated clearly which strains were the 
most potent AML apoptosis inducers and the cluster of those 
specifically leukemia active strains was marked with an 
asterisk (Fig. 2). This group showed high activities against 
AML cells mainly in aqueous extracts. Even though a few of 
these strains contained adenosine like activity, most of the 
strains had bioactivity where we could not identify the 
compound by cell-activity or LC-MS. In addition, there were 
potential strains in other clusters. One example is the organic 
extract of Planktothrix sp. 251, which produced high and 
cytotoxic activity selectively against AML cells. An 
interesting result was that neither we could easily pick a 
genera or a sampling place according to the cluster analysis to 
guide us in the search for anti-leukemic compounds. It thus 
appeared that all genera studied contained strains that were 
potent producers of anti-AML activity, and that a future 
search for novel bioactivity should not be narrowed down to 
one or two genera. On the contrary, a broad approach appears 
to be the best in order to detect many different activities.
 In the studies of Herfindal et al. [77] and Oftedal et al. [70] 
the most of the strains belonged to the genus Anabaena which 
was acknowledged to be fruitful. All of the potent anti-AML 
inducers were Anabaena strains, to mention but a few 
Anabaena sp. XPORK 2A, XPORK 6B, XPORK 35A and 
XSPORK 14D were specifically active against AML cells. 
The two latter studies [82] included several other genera, such 
as Calothrix, Nodularia and Planktothrix. Interestingly, the 
most potent anti-AML strains in the study of Liu et al. [82] 
were Nodularia sp. HAN 37/1 and Anabaena sp. HAN 21/1 
which were almost only representatives of these genera in that 
study. Only one Calothrix strain, Calothrix sp. HAN 24/1, 
showed high anti-AML apoptosis. In addition, the Nostoc sp. 
strains showed high apoptotic activities in the study of Liu et 
al. [82] but the most of these strains were shown to produce 
either microcystins or adenosines or both and thus they were 
active against hepatocytes or OATP-expressing HEK293T 
cell line. The new unpublished data included the most variable 
range of genera and the most potent anti-AML inducers were 
detected from various strains including Planktothrix, 
Calothrix, Nostoc, Trichormus, Anabaena and Leptolyngbya 
subspecies. The new unpublished data thus added many new 
potential genera along the Anabaena and Nodularia. 
However, when screening natural samples and especially 
cyanobacteria the strain identification and isolation to pure 
culture is still a time consuming and difficult task, which is 
often conducted in parallel with, or after testing of the crude 
extracts for bioactivities. This makes it harder to select 
samples based on genus and guides the decision-making even 
further to the sampling places and sampling times. 
 The cyanobacteria were isolated from planktonic, benthic 
and sediment habitats of limnic or brackish water 
environments, in addition to symbiotic strains collected from 
lichen (Fig. 2.). The largest part of the strains were benthic 
cyanobacteria from the Baltic Sea collected from various 
substrates (Fig. 2.), since these are little investigated with 
respect to bioactivity compared to planktonic bloom forming 
species. Symbiotic strains, which were all from genus Nostoc, 
seemed to be less potent producers of anti-AML activity, and 
many of them produced microcystin- and adenosine-like 
activities (Fig. 2.). The benthic habitats harbored many 
interesting activities, for instance the benthic Baltic Sea 
strains from the studies of Herfindal et al. [77] and Oftedal et 
al. [70] as well as strains isolated from sediment of Lake 
Hiidenvesi showed specific anti-AML activity or specific 
activity solely against Molm13 cell line. The benthic strains 
seemed to be overall more interesting targets while many of 
the planktonic cyanobacteria were shown to produce 
hepatotoxins. Fig. 3 illustrates how the majority of the 
hepatocyte-toxic extracts in the new unpublished dataset were 
planktonic cyanobacterial extracts. However, some of the 
planktonic strains also showed specific activities against 
AML cell lines, for instance Planktothrix sp. strains were 
apoptotic against IPC-81 cells.    
 Data from the first studies [70, 77] showed that the anti-
leukemic activities of cyanobacterial extracts resided mainly 
in the aqueous extracts, however we concluded later that also 
the adenosine activity was present in the aqueous extracts. 
Still we could detect anti-leukemic activities in aqueous 
extracts after removing the adenosine activity. As shown in 
Fig. 2 anti-AML activity resides in both extracts, but usually 
in either of the extract, rather than in both extract from one 
strain. This suggests that the anti-AML activity detected in the 
screenings derive from structurally different compounds with 
different chemical properties. Again, this underscores the 
ability of cyanobacteria to produce diverse bioactive 
compounds. The most potent AML apoptosis inducing 
samples in the study of Liu et al. [82] were the organic extract 
of the strain Anabaena sp. HAN 21/1 and the aqueous extract 
of the strain Nodularia sp. 37/1. However, the presence of 
bioactivity in certain extract depends simply on the used 
solvents thus only results from similar methods should be 
compared in concern of the extracts. The change of the 
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extraction method from three-phase extraction to faster two-
phase extraction method did not decrease the amount of 
potential findings. Each extract of cyanobacteria contained all 
the compounds dissolved in solvents. This meant that extracts 
included several compounds, which were interacting and 
could inhibit or enhance each other. Thus extracts may contain 
more than one bioactive compound and the screening results 
against a set of cell lines can vary although the main bioactive 
compound is same in different extracts.  
3.3. LC-MS analysis enhance the results of cell assays 
 A selection of the active samples was further analyzed by 
LC-MS to detect known cytotoxic compounds. In ten of the 
nineteen strains studied, no such compounds were found, even 
among the most potent apoptosis inducers like 
Pseudanabaena sp. HIID B16A. This underscores the 
potential of discovering novel bioactive compounds in 
cyanobacteria from culture collections. Several compound 
groups were however found (Fig. 4.), such as 
anabaenopeptins, hassallidins, putative microviridins and 
microcystins, which were present in the aqueous extraction 
phase. Compounds like aeruginosins, putative cyanobactins 
and depsipeptides resided in both phases. Cyanobactins were 
prenylated and nonprenylated. We found no clear correlation 
between the peptide groups and cytotoxicity data. For 
instance, the aqueous extract of Planktothrix sp. 289 and 
organic extract of Nostoc sp. HIID D1B exhibited no activities 
in cell tests and no compounds could be recognized by LC-
MS, whereas the aqueous extract of Planktothrix sp. 251 and 
278 exhibited no activities in cell tests but several peptide 
groups were present. The organic extracts of Planktothrix sp. 
289 and 278 extracts in addition to aqueous extract of Nostoc 
sp. HIID D1B showed however 100 % activity against 
Molm13 cells but different peptide groups (hassallidins, 
cyanobactins, aeruginosins) were present in the extracts. It is 
thus possible that for each extracts, one or several unknown 
compounds were responsible for the cytotoxic activity, or that 
the active compound(s) belonged to these peptide groups. 
 The aqueous extract of strain HIID D1B was active against 
AML cells and hepatocytes, and we could detect the presence 
of the recently discovered antifungal compound hassallidin, 
whose effect on mammalian cells is not yet described [109, 
110]. In addition, some of the strains (XPORK 5C, XSPORK 
7B, XSPORK 36B) with cytotoxic activity, have been found 
to produce hassallidin variants and hassallidin appears to be 
produced by many cyanobacteria [111]. It is thus possible that 
hassallidin activity was present in these extracts, and it should 
be further investigated if hassallidin caused the cytotoxic 
response, and if so, how hassallidins affect mammalian cell 
signaling.     
 The hepatotoxic microcystins and nodularins induce 
apoptosis selectively in primary hepatocytes due to the 
presence of the organic anion transporter polypeptides 
(OATP) 1B1 and 1B3 [112]. We found that particularly the 
aqueous extracts showed strong apoptotic activity towards 
either primary hepatocytes, or HEK293T cells with enforced 
expression of OATP1B1/1B3 [77, 82]. In the study of 
Herfindal et al. [77] two planktonic cyanobacteria expressed 
strong apoptosis-inducing activity selectively towards 
primary hepatocytes, with morphology consistent with 
microcystin or nodularin induced apoptosis [73, 77, 113]. 
These showed strong activity in aqueous extracts and 
moderate activity in methanol extract against hepatocytes but 
had low cytotoxicity towards the AML-cell lines IPC-81 and 
HL-60. However, we have demonstrated that microcystins 
producing strains fail to induce primary hepatocyte apoptosis 
due to the presence of cyclic peptide antitoxins [105, 114]. In 
the last dataset, several of the strains were known to contain 
microcystins, but some did not produce apoptosis in 
OATP1B1/1B3 expressing cells or primary hepatocytes. We 
concluded that this was due to the presence of cyclic peptide 
antitoxins [91, 105]. Also the LC-MS analyses supported the 
notion that cyanobacteria produce many different active 
agents. For instance from the organic extract of Planktothrix 
sp. 245 we found two different preliminary structures of 
oscillarins and depsipeptides together with cyanobactins and 
anabaenopeptins in addition to small amount of the 
microcystins (de-Me-MC-RR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 4. Occurrence of the cyanobacterial peptide groups and AML 
activity.  __ = Dominant peptide groups in aqueous and organic 
extracts, Pl = Planktothrix sp., N = Nostoc sp. 
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3.4. Cytotoxicity screens leads to identification of novel 
anti-AML compounds 
 Screening of culture collections gives the foundation to 
discover novel bioactive compounds from a great amount of 
strains. Some of the studied cytotoxic strains from the studies 
of Herfindal et al. [77] and Oftedal et al. [70] induced 
intriguing apoptosis morphology and they were later found to 
contain the novel compounds anabaenolysin A and B [115]. 
Anabaenolysins induce lysis of cells by targeting cholesterol 
containing membranes [116]. In total eight of these cytotoxic 
strains were identified to produce anabaenolysin A or B, 
Anabaena sp. XSPORK 27C and 15F being the most potent 
producers [115]. However, extracts from producers of 
anabaenolysins behaved differently; XPORK 15F extracts 
were active against all cell lines tested, but extracts from the 
strain Anabaena sp. XSPORK 2A were mainly active against 
IPC-81 cells. This underlines the diversity of bioactive 
compounds in cyanobacteria, and how a mixture of 
bioactivities can influence the outcome of simple cell based 
assays. It seems therefore reasonable to consider all extracts 
with bioactivity as potent producers of anti AML activity, and 
conclude after for instance a crude fractionation of the extracts 
is performed.      
 The strain Anabaena sp. HAN 21/1, which was screened 
in the study of Liu et al. [82], was recently detected to produce 
several variants of scytophycins [117]. This strain was 
detected to have specific and high antileukemic activity in 
both aqueous and organic extracts suggesting that 
scytophycins were the source of the detected activity. As more 
cyanobacteria strains are screened and compounds are 
identified it is unavoidable to rediscover “old” compounds. 
Still, even old compounds can reveal new aspects if they are 
tested in a new manner. For instance hierridin B was isolated 
from Cyanobium sp. on the basis of activity against colorectal 
adenocarcinoma cell line [118]. However, hierridin B had 
been previously described as a mild antiplasmodial compound 
[119]. On the contrary scytophycins have been described as 
cytotoxic compounds from beginning [120, 121].  
3.5. Concluding remarks 
 With this review of new and previous data, we 
demonstrate the potency of cyanobacterial culture collections 
as source for novel compounds with a desired bioactivity, in 
this case anti-AML activity. Although Anabaena species from 
the Baltic Sea appeared to be the best producers of activity 
selective towards AML cells, most of the studied genera had 
one or more representatives with such activity. Moreover, 
benthic, planktonic and symbiotic cyanobacteria were 
represented with the desired activity, but the benthic strains 
were the most potent producers. It appears that bioactive 
compounds can be found in virtually all cyanobacteria, 
irrespective of genera, sampling site or habitat. Perhaps more 
importantly, the bioactivity is present even after several years 
in culture, as previously demonstrated in a study where a 
strain retained the bioactivity after more than 50 years in 
culture [79]. Even though there is an ever-increasing chance 
for rediscovery of known compounds, our preliminary LC-
MS screens failed to identify known compounds from several 
of the active strains, showing that cyanobacteria produce still 
unknown secondary metabolites which may have valuable 
features in drug discovery. These novel metabolites may be 
used also in combination with known drugs to improve 
disease treatment. One option is therefore to include known 
drugs in the screens to detect activities that increase the AML 
cell response to commonly used cytostatics such as 
daunorubicin or AraC. The new structures and mechanisms of 
action can also be used for development of new drugs.
 Here we added yet another group of cyanobacteria 
samples into the studies of anti-leukemic compounds from 
cyanobacteria and detected a variable cytotoxic features 
varying from generic cytotoxicity to AML specific activities. 
We found a variable set of strains which should be further 
examined to reveal the active compounds in extracts. Together 
this clearly supports the maintenance of culture collections for 
future screening programs also for other activities than anti-
cancer. 
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